Summary

Report Scope:

The current report provides detailed exposure to the cell and gene therapy market. This report also highlights the current and future market potential of CGTs along with a detailed analysis of the drivers, restraints, and opportunities in the market. The report also covers market projections to 2026 and market rank for key market players. It also covers the competitive environment and includes a pipeline analysis. The report details the market share of CGTs based on product and by application. The market is segmented into rare diseases, oncology, hematology, cardiovascular, neurology and others based on application. The scope of the report does not include RNA-based products.

By region, the market has been segregated into North America, Europe, Asia-Pacific, and the Rest of the World (RoW). The North America region includes countries such as the U.S., Canada and Mexico, Europe includes countries Germany, U.K., France, and Rest of Europe, and the Asia-Pacific includes countries China, Australia, Japan, and Rest of Asia-Pacific. For market estimates, data have been provided for 2019 as the historic year, 2020 as the base year and a forecast for 2026.

Report Includes:

- 20 data tables and 25 additional tables
- An overview of the global market for cell and gene therapy (CGT) products and their applications
- Analyses of the global market trends, with historic data from 2019-2020, estimates for 2021, and projections of compound annual growth rates (CAGRs) through 2026
- Evaluation and forecast the overall market size for cell and gene therapy, forecasted growth trends, and corresponding market share analysis by product type, therapy type, application, and region
- Highlights of the upcoming market potential of cell and gene therapy products and areas of focus to forecast this market into various segments and sub-segments
- In-depth information (facts and figures) concerning market drivers, market deterrents and other demographic and economic factors that will drive future demand for this market
- Identification of novel therapeutic products and promising new technologies still in the development and testing stage, and assess the probability that they will be commercialized successfully in the next five years
- Review of emerging companies and the leading competitors in the prevailing cell and gene therapy market, and their global company share analysis
- Impact of COVID-19 pandemic on cell and gene therapy market and related biotech industry
- Review of pipeline analysis and the total number of CGT clinical trials by clinical trial phase, disease indication, and geography
- Descriptive company profiles of the major global players, including Novartis, Orchard Therapeutics plc, Pharmicell Co. Ltd., Sibiono Genetech Co. Ltd., Vericel Corp. and Bristol-Myers Squibb Co.

ページTOPに戻る

Table of Contents

Table of Contents
Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing This Study
Scope of This Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports
Chapter 2 Summary and Highlights
Highlights of the Market for Cell and Gene Therapy
Chapter 3 Cell and Gene Therapy: Background and Technology
Cell and Gene Therapy Overview
Chapter 4 Market Dynamics
Market Dynamics
Market Drivers
Market Restraints
Market Opportunities
Chapter 5 Market Breakdown by Therapy Type
Global Market for Cell and Gene Therapy
Market Analysis
Cell Therapy
Market Size and Forecast
Gene-Modified Cell Therapy
Market Size and Forecast
Gene Therapy
Market Size and Forecast
Global Market for Gene Modified Cell Therapy and Gene Therapy by Vector Type
Market Analysis
Adeno-Associated Viral (AAV) Vectors
Retroviral Vectors
Lentiviral Vectors
Others
Chapter 6 Market Breakdown by Product
Global Market for Cell and Gene Therapy by Product
Zolgensma
Yescarta
Kymriah
Zynteglo
Maci
Tecartus
Epicel
Others
Chapter 7 Market Breakdown by Application
Global Market for CGTs by Application
Rare Diseases
Oncology
Hematology
Ophthalmology
Neurology
Other Therapeutic Areas
Cardiovascular Diseases
Chapter 8 Market Breakdown by Region
Global Market for Cell and Gene Therapy by Region
North America
U.S.
Canada
Mexico
Europe
Germany
U.K.
France
Rest of Europe
Asia-Pacific
Japan
China
Australia
Rest of Asia-Pacific
Rest of the World
Chapter 9 Impact of the COVID-19 Pandemic
Introduction
Outbreak
Symptoms of COVID-19
Progression of COVID-19
Incubation Period
Epidemiology
Global Confirmed COVID-19 Cases and Deaths
Collaboration Between Organizations and Governments
Spread of Disease
COVID-19 Impact on the Cell and Gene Therapy Market
Chapter 10 Pipeline Analysis
Pipeline Analysis
Pipeline of Supplemental Indication and Formulation Expansions
Drugs Pending Approval
Chapter 11 Competitive Landscape
Competitive Landscape: Overview
Market Share Analysis
Strategic Acquisitions and Collaborations
Chapter 12 Company Profiles
AMGEN INC.
BLUEBIRD BIO INC.
BRISTOL-MYERS SQUIBB CO.
DENDREON PHARMACEUTICALS LLC
GILEAD SCIENCES INC.
NOVARTIS INTERNATIONAL AG
ORCHARD THERAPEUTICS PLC.
PHARMICELL CO. LTD.
SIBIONO GENETECH CO. LTD.
VERICEL CORP.
Chapter 13 Appendix: List of Acronyms